AHA 2020: EAGLE Trial Results

Published: 11 Nov 2020

  • Views:

    Views Icon 29
  • Likes:

    Heart Icon 0

Can the use of Artificial Intelligent (AI) enabled ECGs aid the detection of asymptomatic low EF in primary care?

Dr Xiaoxi Yao (Mayo Clinic, Rochester, MN, US) and Dr Peter Noseworthy (Mayo Clinic, Rochester, MN, US) discuss the results from the EAGLE (ECG AI-guided Screening For Low Ejection Fraction) RCT, a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.

1. What are the objectives of EAGLE?
2. What is the trial design?
3. What were the results?
4. What conclusions can be made?
5. What are the next steps?
6. What are the take-home messages for clinicians?
7. How can these findings support future implementations of AI screening?

Recorded remotely from Rochester, 2020.

The individuals featured were alone in a non-patient care, non-public setting, and therefore in compliance with Mayo Clinic’s COVID-19 safety guidelines while unmasked.

Interviewer: Victoria Perroud
Recording editor: Mike Knight